Citations

Clear

2429 citation(s) found for "Shah, SS".

Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment
Yaqoob, Usman , Cao, Sheng , Shergill, Uday, Jagavelu, Kumaravelu , Geng, Zhimin , Yin, Meng , Assuncao, Thiago M. de , Cao, Ying , Szabolcs, Anna, Thorgeirsson, Snorri S., Yang, Ju , Roberts, Lewis R. , Shah, Vijay H. , Yaqoob, Usman , Schwartz, Martin A. , Ehman, Richard L. , Mukhopadhyay, Debabrata , Roberts, Lewis R , Yin, Meng

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 72 | Issue: 16 | Pages: 4047-4059

10.1158/0008-5472.can-11-3907 | PMID 22738912 Get It

Abstract The tumor microenvironment, including stromal myofibroblasts and associated matrix proteins, regulates cancer cell invasion and proliferation. Here, we report that neuropilin-1 (NRP-1) orchestrates communications between myofibroblasts and soluble fibronectin that promote α5β1 integrin–dependent fibronectin fibril assembly, matrix stiffness, and tumor growth. Tumor growth and fibronectin fibril assembly were reduced by genetic depletion or antibody neutralization of NRP-1 from stromal myofibroblasts in vivo. Mechanistically, the increase in fibronectin fibril assembly required glycosylation of serine 612 of the extracellular domain of NRP-1, an intact intracellular NRP-1 SEA domain, and intracellular associations between NRP-1, the scaffold protein GIPC, and the nonreceptor tyrosine kinase c-Abl that augmented α5β1 fibronectin fibril assembly activity. Analysis of human cancer specimens established an association between tumoral NRP-1 levels and clinical outcome. Our findings indicate that NRP-1 activates the tumor microenvironment, thereby promoting tumor growth. These results not only identify new molecular mechanisms of fibronectin fibril assembly but also have important implications for therapeutic targeting of the myofibroblast in the tumor microenvironment. Cancer Res; 72(16); 4047–59. ©2012 AACR.
Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia
Houten, Holly K. Van , Shah, Nilay D. , Wermers, Robert A. , Smith, Steven A., McCoy, Rozalina G. , Ziegenfuss, Jeanette Y.

Mayo Clinic

Diabetes Care | June 15, 2012 | Volume: 35 | Issue: 9 | Pages: 1897-1901

10.2337/dc11-2054 | PMID 22699297 Get It

OBJECTIVE Hypoglycemia is a cause of significant morbidity among patients with diabetes and may be associated with greater risk of death. We conducted a retrospective study to determine whether patient self-report of severe hypoglycemia is associated with increased mortality. RESEARCH DESIGN AND METHODS Adult patients (N = 1,020) seen in a specialty diabetes clinic between August 2005 and July 2006 were questioned about frequency of hypoglycemia during a preencounter interview; 7 were lost to follow-up and excluded from analysis. Mild hypoglycemia was defined as symptoms managed without assistance, and severe hypoglycemia was defined as symptoms requiring external assistance. Mortality data, demographics, clinical characteristics, and Charlson comorbidity index (CCI) were obtained from the electronic medical record after 5 years. Patients were stratified by self-report of hypoglycemia at baseline, demographics were compared using the two-sample t test, and risk of death was expressed as odds ratio (95% CI). Associations were controlled for age, sex, diabetes type and duration, CCI, HbA1c, and report of severe hypoglycemia. RESULTS In total, 1,013 patients with type 1 (21.3%) and type 2 (78.7%) diabetes were questioned about hypoglycemia. Among these, 625 (61.7%) reported any hypoglycemia, and 76 (7.5%) reported severe hypoglycemia. After 5 years, patients who reported severe hypoglycemia had 3.4-fold higher mortality (95% CI 1.5–7.4; P = 0.005) compared with those who reported mild/no hypoglycemia. CONCLUSIONS Self-report of severe hypoglycemia is associated with 3.4-fold increased risk of death. Patient-reported outcomes, including patient-reported hypoglycemia, may therefore augment risk stratification and disease management of patients with diabetes.
A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation
Bharucha, Adil E. , Low, Phillip A. , Camilleri, Michael , Veil, Erica B., Burton, Duane D. , Kudva, Yogish C. , Shah, Pankaj, Gehrking, Tonette L., Zinsmeister, Alan R.

Mayo Clinic

Gut | June 7, 2012 | Volume: 62 | Issue: 5 | Pages: 708-715

10.1136/gutjnl-2012-302483 | PMID 22677718 Get It

Objectives Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors increase colonic motility. This study evaluated the effects of a cholinesterase inhibitor on gastrointestinal and colonic transit and bowel function in diabetic patients with constipation. Design After a 9-day baseline period, 30 patients (mean±SEM age 50±2 years) with diabetes mellitus (18 type 1, 12 type 2) and chronic constipation without defaecatory disorder were randomised to oral placebo or pyridostigmine, starting with 60 mg three times a day, increasing by 60 mg every third day up to the maximum tolerated dose or 120 mg three times a day; this dose was maintained for 7 days. Gastrointestinal and colonic transit (assessed by scintigraphy) and bowel function were evaluated at baseline and the final 3 and 7 days of treatment, respectively. Treatment effects were compared using analysis of covariance, with gender, body mass index and baseline colonic transit as covariates. Results 19 patients (63%) had moderate or severe autonomic dysfunction; 16 (53%) had diabetic retinopathy. 14 of 16 patients randomised to pyridostigmine tolerated 360 mg daily; two patients took 180 mg daily. Compared with placebo (mean±SEM 1.98±0.17 (baseline), 1.84±0.16 (treatment)), pyridostigmine accelerated (1.96±0.18 (baseline), 2.45±0.2 units (treatment), p<0.01) overall colonic transit at 24 h, but not gastric emptying or small-intestinal transit. Treatment effects on stool frequency, consistency and ease of passage were significant (p≤0.04). Cholinergic side effects were somewhat more common with pyridostigmine (p=0.14) than with placebo. Conclusions Cholinesterase inhibition with oral pyridostigmine accelerates colonic transit and improves bowel function in diabetic patients with chronic constipation. Clinical trial registration number TrialRegNo (NCT 00276406).
Atypical Omenn Syndrome due to Adenosine Deaminase Deficiency
Joshi, Avni Y. , Ham, Erin K., Shah, Neel , Dong, Xiangyang, Khan, Shakila P. , Abraham, Roshini S.

Mayo Clinic

Case Reports in Immunology | June 1, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-4

10.1155/2012/919241 | PMID 25954555 Get It

We present here a novel case of an atypical Omenn syndrome (OS) phenotype due to mutations in theADAgene encoding adenosine deaminase. This case is noteworthy for a significant increase in circulating CD56brightCD16- cytokine-producing NK cells after treatment with steroids for skin rash.
Which design for which question? An exploration toward a translation table for comparative effectiveness research
Montori, Víctor M. , Kim, Simon P. , Shah, Nilay D. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Journal of Comparative Effectiveness Research | May 18, 2012 | Volume: 1 | Issue: 3 | Pages: 271-279

10.2217/cer.12.24 | PMID 24237408 Get It

In this paper, we explore the relative value that different methods offer in answering some stereotypical comparative effectiveness research questions with the goal of informing development of a ‘translation table’ – a selection tool for choosing appropriate methods for specific comparative effectiveness research questions. This paper was written as a parallel effort to Greenfield and Kaplan (also in this volume) to support the endeavor described in the manuscript by Tunis et al. (also in this volume). Originally based on four cases, the current article has been shortened to two cases for the current discussion. These cases represent research priorities proposed to orient the work of the Patient-Centered Outcomes Research Institute, comparative clinical effectiveness and comparative health services.
Obstetric Complications of Ureteroscopy During Pregnancy
Johnson, Elizabeth B., Krambeck, Amy E. , White, Wesley M. , Hyams, Elias S. , Beddies, John, Marien, Tracy , Shah, Ojas , Matlaga, Brian R., Pais, Vernon M.

Mayo Clinic

Journal of Urology | May 15, 2012 | Volume: 188 | Issue: 1 | Pages: 151-154

10.1016/j.juro.2012.02.2566 | PMID 22591961 Get It

The relationship of postoperative complications with in‐hospital outcomes and costs after renal surgery for kidney cancer
Kim, Simon P. , Leibovich, Bradley C. , Shah, Nilay D. , Weight, Christopher , Han, Leona C., Boorjian, Stephen A. , Thompson, R. Houston, Borah, Bijan J.

Mayo Clinic

BJU International | May 7, 2012 | Volume: 111 | Issue: 4 | Pages: 580-588

10.1111/j.1464-410x.2012.11122.x | PMID 22564425 Get It

What's known on the subject? and What does the study add? Postoperative complications for open radical nephrectomy ( ORN ), laparoscopic radical nephrectomy ( LRN ), and open partial nephrectomy ( OPN ) and its relationship with hospitalisation costs and mortality remain poorly described. The present population‐based study suggests modest differences in postoperative complications estimated at 27%, 23%, and 24% among patients with kidney cancer undergoing ORN , LRN , and OPN , respectively. Moreover, postoperative complications were associated with higher mortality, length of stay and total costs of hospitalisation. Objectives The association of complications after renal surgery for renal cell carcinoma ( RCC ) with in‐hospital mortality and costs remains to be defined. To describe the incidence of complications after open radical nephrectomy ( ORN ), laparoscopic RN ( LRN ), and open partial nephrectomy ( OPN ); and to evaluate its relationship with in‐hospital mortality and total costs. Patients and Methods We identified 49 983 individuals who underwent ORN (35 712), LRN (5327), or OPN (8944) for RCC at 2037 hospitals from the Nationwide Inpatient Sample 2001–2008. The outcomes assessed were in‐hospital mortality and total hospitalisation costs. Multivariable logistic regression and generalised estimating equations were used to test the associations between complications and in‐hospital mortality and total costs. Results With 26.0% of patients experiencing postoperative complications, there were modest differences in the proportion of patients with complications after ORN , LRN , and OPN at 27.0%, 22.6%, and 24.0%, respectively ( P < 0.001). After adjusting for patient and hospital variables, postoperative complications resulted in higher odds of in‐hospital death for ORN (odds ratio [ OR ] 7.20; P < 0.001), LRN ( OR 12.04; P < 0.001), and OPN ( OR 7.82; P < 0.001). Adjusted total costs also rose significantly with the presence of any postoperative complications compared with those without any complications for ORN ($21 242 vs $13 183; P < 0.001), LRN ($19 548 vs $12 555; P < 0.001), and OPN ($18 883 vs $12 098; P < 0.001). Conclusions With about a quarter of patients experiencing postoperative complications, adverse events for ORN , LRN , and OPN carry a significant risk of in‐hospital death and higher total costs. Efforts to reduce postoperative complications may correlate with substantial reductions in hospital mortality and total costs.
The role of genetic breast cancer susceptibility variants as prognostic factors
Fasching, Peter A. , Cox, Angela , Nevanlinna, Heli , Bojesen, Stig E. , Karn, Thomas , Leeuwen, Flora E. van , Veer, Laura van ‘t , Udo, Renate, Dunning, Alison M. , Greco, Dario , Aittomäki, Kristiina, Blomqvist, Carl , Shah, Mitul , Nordestgaard, Børge G. , Flyger, Henrik, Hopper, John L. , Southey, Melissa C. , Apicella, Carmel, García‐Closas, Montserrat , Sherman, Mark E., Lissowska, Jolanta , Seynaeve, Caroline, Huijts, Petra E.A., Tollenaar, Rob A.�E.�M. , Ekici, Arif B. , Rauh, Claudia , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli-Matti, Hartikainen, Jaana M. , Andrulis, Irene L. , Özçelik, Hilmi, Mulligan, Anna Marie , Glendon, Gord, Czene, Kamila , Liu, Jianjun , Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Eilber, Ursula, Nickels, Stefan , Dörk, Thilo , Schiekel, Maria, Bremer, Michael , Park‐Simon, Tjoung‐Won, Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , Hooning, Maartje J. , Jager, Agnes , Kriege, Mieke, Lindblom, Annika , Margolin, Sara , Stevens, Kristen N., Kosel, Matthew , Cross, Simon S. , Balasubramanian, Sabapathy P. , Reed, Malcolm , Miron, Alexander, John, Esther M. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Kauppila, Saila , Burwinkel, Barbara , Schneeweiß, Andreas , Sohn, Christof , Chenevix‐Trench, Georgia , Investigators, kConFab, Lambrechts, Diether , Dieudonné, Anne-Sophie, Hatse, Sigrid , Limbergen, Erik Van, Zamora, M. Pilar , Peissel, Bernard , Loris, Bernard, Peterlongo, Paolo , Rajaraman, Preetha , Beckmann, Matthias W. , Slamon, Dennis J. , Phillips, Kelly‐Anne , Humphreys, Manjeet K., Easton, Douglas F. , Schmidt, Marjanka K. , Thorne, Heather , Purrington, Kristen S. , Lambrechts, Diether , Pharoah, Paul D.P. , Broeks, Annegien , Veer, Laura J. van’t , Ziogas, Argyrios , Mannermaa, Arto, Hall, Per N , Martens, John W.M. , Couch, Fergus J. , Olson, Janet E. , Marmé, Frederik , Investigators, kConFab, Benı́tez, Javier , Milne, Roger L. , Pérez, José Ignacio Arias , Bonanni, Bernardo , Schonfeld, Sara J. , Anton‐Culver, Hoda , Devilee, Peter , Figueroa, Jonine D. , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Lissowska, Jolanta , John, Esther M , Southey, Melissa C , Dunning, Alison M , Lambrechts, Diether , Cox, Angela , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Hartikainen, Jaana M , Chenevix-Trench, Georgia , Czene, Kamila , Pylkäs, Katri , Baglietto, Laura , Bojesen, Stig E , Purrington, Kristen S , Phillips, Kelly-Anne , Lindblom, Annika , Liu, Jing

Mayo Clinic

Human Molecular Genetics | April 25, 2012 | Volume: 21 | Issue: 17 | Pages: 3926-3939

10.1093/hmg/dds159 | PMID 22532573 Get It

Achalasia: A Diagnosis That's Hard to Swallow
Ajani, Shahnaz, Shah, Neel , Vlahakis, Nicholas E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 15, 2012 | Volume: 185 | Issue: 8 | Pages: 893-893

10.1164/rccm.201107-1225im | PMID 22505754 Get It

The Implications of Hospital Acquired Adverse Events on Mortality, Length of Stay and Costs for Patients Undergoing Radical Cystectomy for Bladder Cancer
Kim, Simon P. , Shah, Nilay D. , Karnes, R. Jeffrey , Weight, Christopher , Frank, Igor, Moriarty, James P. , Han, Leona C., Tollefson, Matthew K. , Boorjian, Stephen A. , Borah, Bijan J.

Mayo Clinic

Journal of Urology | April 11, 2012 | Volume: 187 | Issue: 6 | Pages: 2011-2017

10.1016/j.juro.2012.01.077 | PMID 22498229 Get It